Mobile website
Archive > Volume 24 Issue 11 > 2017,24(11):1299-1303. DOI:10.3872/j.issn.1007-385X.2017.11.010 Prev Next
Clinical Research
Expression of taurine upregulated gene 1 in the patients with DLBCL and its relationship with prognosis of the patients
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To explore expression of taurine upregulated gene 1 (TUG1) in tissue specimens of the patients with diffuse large B-cell lymphoma (DLBCL) and to analyze correlation between expression of TUG1 and clinical features as well as prognosis of the patients with DLBCL. Methods: Tissue specimens of 108 patients who were diagnosed as DLBCL in Department of Hematology, the 1st Hospital affiliated to Southwestern Medical University during January 2011 to December 2016 and 47 patients with reactive lymphoid hyperplasia (RLH) during the same period were collected. qPCR assay was used to detect expressions of TUG1 mRNA in the tissue specimens of the patients with DLBCL or RLH. The relationship between expression level of TUG1 mRNA and clinical pathological features of the patients with DLBCL as well as factors affecting survival time and prognosis of the patients with DLBCL were analyzed by Chi-Square test, Kaplan-Meier assay, univariate and multivariate assays respectively. Results:Expression of TUG1 mRNA in the patients with DLBCL was obviously higher than that in the patients with RLH (6.108±0.332 vs 1.231±0.095, P<0.01). Expression of TUG1 mRNA was evidently related to disease staging,tumor size, B cell symptom, IPI index, GCB subtype and chemotherapy sensitivity in the patients with DLBCL (all P<0.01). Expression of TUG1 mRNA, disease staging and tumor size were the factors affecting over survival time (OS) of the patients with DLBCL (all P<0.05). Expression of TUG1 mRNA, disease staging, IPI index and chemotherapy sensitivity were the factors effecting on prognosis of the patients with DLBCL. Conclusion: TUG1 mRNA was highly expressed in the DLBCL tissues and was the independent factor effecting on prognosis of the patients with DLBCL. TUG1 might be as a novel marker which evaluates prognosis of the patients with DLBCL and as a po-tential target point for gene therapy of DLBCL.
Keywords:
Project Supported:
Clc Number:
